Abstract：
Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.
摘要：
转移性前列腺癌是一种常见且致命的疾病。自[177Lu]Lu-PSMA-617批准以来，靶向放射性核素治疗（TRT）已成为一种现成的治疗选择。目前正在研究各种分子用于前列腺癌中的TRT。我们回顾了用于靶向前列腺癌细胞和优化药代动力学的同位素和载体的各种组合。有希望的创新包括化学修饰以改善生物分布，识别新目标，以及新型放射性同位素如α发射体的使用。患者总结：我们的小型综述总结了靶向放射性药物治疗转移性前列腺癌的研究。几种有前途的放射性药物正在临床试验中进行评估，但更多的研究是必要的之前，这些可以用于常规临床实践。
